Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Biotech
Cash-strapped Medigene lays off 40%, pauses plan to enter clinic
Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to its T cell receptor-guided therapies.
James Waldron
Nov 26, 2024 6:52am
Roche inks $1.5B Poseida buyout to land off-the-shelf CAR-Ts
Nov 26, 2024 6:00am
Patient put in critical condition by Neurogene gene therapy dies
Nov 22, 2024 3:57am
Novartis signs $1.1B deal for muscular dystrophy biotech
Nov 21, 2024 8:19am
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
Nov 20, 2024 12:00pm
Neurogene stops Batten gene therapy after FDA denies request
Nov 19, 2024 6:30am
More News
Regenxbio starts pivotal study for DMD gene therapy
Nov 18, 2024 2:24pm
CSL Behring shuts down California cell and gene therapy R&D site
Nov 18, 2024 8:35am
Neurogene acts as gene therapy puts person in critical condition
Nov 18, 2024 8:33am
DMD gene therapy uses cells to stitch together mRNA in mice
Nov 14, 2024 3:10pm
See more stories
